Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein

Yi Nan Chen, Lyn A. Mickley, Arnold M. Schwartz, Edward M. Acton, Jaulang Hwang, Antonio T. Fojo

Research output: Contribution to journalArticle

191 Citations (Scopus)

Abstract

Development of multidrug resistance due to overexpression of P-glycoprotein (Pgp), a cell membrane drug efflux pump, occurs commonly during in vitro selections with adriamycin (Adr). Pgp-mediated drug resistance can be overcome by the calcium channel blocker verapamil (Vp), which acts as a competitive inhibitor of drug binding and efflux. In order to identify other mechanisms of Adr resistance, we isolated an Adr-resistant subline by selecting the human breast cancer cell line MCF-7 with incremental increases of Adr in the presence of 10 μg/ml verapamil. The resultant MCF-7/AdrVp subline is 900-fold resistant to Adr, does not overexpress Pgp, and does not exhibit a decrease in Adr accumulation. It exhibits a unique cross-resistance pattern: high cross-resistance to the potent Adr analogue 3′-deamino-3′-(3-cyano-4-morpholinyl)doxorubicin, lower cross-resistance to the alkylating agent melphalan, and a sensitivity similar to the parental cell line to vinblastine. The levels of glutathione and glutathione S-transferase are similar in the parental line and the Adr-resistant subline. Topoisomerase II-DNA complexes measured by the potassium-sodium dodecyl sulfate precipitation method shows a 2-3 fold decrease in the resistant subline. The MCF-7/ AdrVp cells overexpress a novel membrane protein with an apparent molecular mass of 95 kDa. Polyclonal antibodies raised against the P-95 protein demonstrate a correlation between the level of expression and Adr resistance. Removal of Adr but not verapamil from the selection media results in a decline in P-95 protein levels that parallels a restoration of sensitivity to Adr. Immunohistochemistry demonstrates localization of the P-95 protein on the cell surface. The demonstration of high levels of the protein in clinical samples obtained from patients refractory to Adr suggests that this protein may play a role in clinical drug resistance.

Original languageEnglish
Pages (from-to)10073-10080
Number of pages8
JournalJournal of Biological Chemistry
Volume265
Issue number17
Publication statusPublished - Jun 15 1990
Externally publishedYes

Fingerprint

Doxorubicin
Membrane Proteins
Cells
Breast Neoplasms
P-Glycoprotein
Verapamil
3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin
Proteins
Drug Resistance
Pharmaceutical Preparations
Cell Line
Type II DNA Topoisomerase
Melphalan
Vinblastine
Alkylating Agents
MCF-7 Cells
Calcium Channel Blockers
Molecular mass
Multiple Drug Resistance
Cell membranes

ASJC Scopus subject areas

  • Biochemistry

Cite this

Chen, Y. N., Mickley, L. A., Schwartz, A. M., Acton, E. M., Hwang, J., & Fojo, A. T. (1990). Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. Journal of Biological Chemistry, 265(17), 10073-10080.

Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. / Chen, Yi Nan; Mickley, Lyn A.; Schwartz, Arnold M.; Acton, Edward M.; Hwang, Jaulang; Fojo, Antonio T.

In: Journal of Biological Chemistry, Vol. 265, No. 17, 15.06.1990, p. 10073-10080.

Research output: Contribution to journalArticle

Chen, Yi Nan ; Mickley, Lyn A. ; Schwartz, Arnold M. ; Acton, Edward M. ; Hwang, Jaulang ; Fojo, Antonio T. / Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. In: Journal of Biological Chemistry. 1990 ; Vol. 265, No. 17. pp. 10073-10080.
@article{f98b085d846645c6aca82c8f1a883e83,
title = "Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein",
abstract = "Development of multidrug resistance due to overexpression of P-glycoprotein (Pgp), a cell membrane drug efflux pump, occurs commonly during in vitro selections with adriamycin (Adr). Pgp-mediated drug resistance can be overcome by the calcium channel blocker verapamil (Vp), which acts as a competitive inhibitor of drug binding and efflux. In order to identify other mechanisms of Adr resistance, we isolated an Adr-resistant subline by selecting the human breast cancer cell line MCF-7 with incremental increases of Adr in the presence of 10 μg/ml verapamil. The resultant MCF-7/AdrVp subline is 900-fold resistant to Adr, does not overexpress Pgp, and does not exhibit a decrease in Adr accumulation. It exhibits a unique cross-resistance pattern: high cross-resistance to the potent Adr analogue 3′-deamino-3′-(3-cyano-4-morpholinyl)doxorubicin, lower cross-resistance to the alkylating agent melphalan, and a sensitivity similar to the parental cell line to vinblastine. The levels of glutathione and glutathione S-transferase are similar in the parental line and the Adr-resistant subline. Topoisomerase II-DNA complexes measured by the potassium-sodium dodecyl sulfate precipitation method shows a 2-3 fold decrease in the resistant subline. The MCF-7/ AdrVp cells overexpress a novel membrane protein with an apparent molecular mass of 95 kDa. Polyclonal antibodies raised against the P-95 protein demonstrate a correlation between the level of expression and Adr resistance. Removal of Adr but not verapamil from the selection media results in a decline in P-95 protein levels that parallels a restoration of sensitivity to Adr. Immunohistochemistry demonstrates localization of the P-95 protein on the cell surface. The demonstration of high levels of the protein in clinical samples obtained from patients refractory to Adr suggests that this protein may play a role in clinical drug resistance.",
author = "Chen, {Yi Nan} and Mickley, {Lyn A.} and Schwartz, {Arnold M.} and Acton, {Edward M.} and Jaulang Hwang and Fojo, {Antonio T.}",
year = "1990",
month = "6",
day = "15",
language = "English",
volume = "265",
pages = "10073--10080",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "17",

}

TY - JOUR

T1 - Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein

AU - Chen, Yi Nan

AU - Mickley, Lyn A.

AU - Schwartz, Arnold M.

AU - Acton, Edward M.

AU - Hwang, Jaulang

AU - Fojo, Antonio T.

PY - 1990/6/15

Y1 - 1990/6/15

N2 - Development of multidrug resistance due to overexpression of P-glycoprotein (Pgp), a cell membrane drug efflux pump, occurs commonly during in vitro selections with adriamycin (Adr). Pgp-mediated drug resistance can be overcome by the calcium channel blocker verapamil (Vp), which acts as a competitive inhibitor of drug binding and efflux. In order to identify other mechanisms of Adr resistance, we isolated an Adr-resistant subline by selecting the human breast cancer cell line MCF-7 with incremental increases of Adr in the presence of 10 μg/ml verapamil. The resultant MCF-7/AdrVp subline is 900-fold resistant to Adr, does not overexpress Pgp, and does not exhibit a decrease in Adr accumulation. It exhibits a unique cross-resistance pattern: high cross-resistance to the potent Adr analogue 3′-deamino-3′-(3-cyano-4-morpholinyl)doxorubicin, lower cross-resistance to the alkylating agent melphalan, and a sensitivity similar to the parental cell line to vinblastine. The levels of glutathione and glutathione S-transferase are similar in the parental line and the Adr-resistant subline. Topoisomerase II-DNA complexes measured by the potassium-sodium dodecyl sulfate precipitation method shows a 2-3 fold decrease in the resistant subline. The MCF-7/ AdrVp cells overexpress a novel membrane protein with an apparent molecular mass of 95 kDa. Polyclonal antibodies raised against the P-95 protein demonstrate a correlation between the level of expression and Adr resistance. Removal of Adr but not verapamil from the selection media results in a decline in P-95 protein levels that parallels a restoration of sensitivity to Adr. Immunohistochemistry demonstrates localization of the P-95 protein on the cell surface. The demonstration of high levels of the protein in clinical samples obtained from patients refractory to Adr suggests that this protein may play a role in clinical drug resistance.

AB - Development of multidrug resistance due to overexpression of P-glycoprotein (Pgp), a cell membrane drug efflux pump, occurs commonly during in vitro selections with adriamycin (Adr). Pgp-mediated drug resistance can be overcome by the calcium channel blocker verapamil (Vp), which acts as a competitive inhibitor of drug binding and efflux. In order to identify other mechanisms of Adr resistance, we isolated an Adr-resistant subline by selecting the human breast cancer cell line MCF-7 with incremental increases of Adr in the presence of 10 μg/ml verapamil. The resultant MCF-7/AdrVp subline is 900-fold resistant to Adr, does not overexpress Pgp, and does not exhibit a decrease in Adr accumulation. It exhibits a unique cross-resistance pattern: high cross-resistance to the potent Adr analogue 3′-deamino-3′-(3-cyano-4-morpholinyl)doxorubicin, lower cross-resistance to the alkylating agent melphalan, and a sensitivity similar to the parental cell line to vinblastine. The levels of glutathione and glutathione S-transferase are similar in the parental line and the Adr-resistant subline. Topoisomerase II-DNA complexes measured by the potassium-sodium dodecyl sulfate precipitation method shows a 2-3 fold decrease in the resistant subline. The MCF-7/ AdrVp cells overexpress a novel membrane protein with an apparent molecular mass of 95 kDa. Polyclonal antibodies raised against the P-95 protein demonstrate a correlation between the level of expression and Adr resistance. Removal of Adr but not verapamil from the selection media results in a decline in P-95 protein levels that parallels a restoration of sensitivity to Adr. Immunohistochemistry demonstrates localization of the P-95 protein on the cell surface. The demonstration of high levels of the protein in clinical samples obtained from patients refractory to Adr suggests that this protein may play a role in clinical drug resistance.

UR - http://www.scopus.com/inward/record.url?scp=0025322402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025322402&partnerID=8YFLogxK

M3 - Article

C2 - 1972154

AN - SCOPUS:0025322402

VL - 265

SP - 10073

EP - 10080

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 17

ER -